Long-Term Use of Besremi in Polycythemia Vera: 5... - MPN Voice

MPN Voice

10,887 members15,205 posts

Long-Term Use of Besremi in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Manouche profile image
14 Replies

« Patients with polycythemia vera (PV) require life-long treatment to prevent thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (BESREMi®; hereafter ropeg) may ultimately modify the natural history of PV by selectively targeting the malignant clone. In the PROUD-PV/CONTINUATION-PV studies, long-term treatment with ropeg was compared with standard cytoreductive therapy regarding thromboembolic and other adverse events as well as evolution of hematologic and molecular parameters over five years. »

ash.confex.com/ash/2020/web...

Written by
Manouche profile image
Manouche
To view profiles and participate in discussions please or .
14 Replies
Aldebaran25 profile image
Aldebaran25

Thank you. Very encouraging 😊

MPort profile image
MPort

Thanks for posting. This is encouraging. I wonder if those of us on Pegasys will be able to switch over?

Manouche profile image
Manouche in reply toMPort

They will, although some haems will be reluctant to do so if their patients are doing well under Pegasys.

hunter5582 profile image
hunter5582

More promising data for the use of Besremi. Besremi was mentioned in the recent MPN Advocacy Intl. Webinar with hope that it will be much easier for PV patients to access the drug once it is FDA approved for PV. Hopefully it will be so.

ggrana profile image
ggrana

Anyone know when it’s coming to the USA?

BeHealthy1986 profile image
BeHealthy1986 in reply toggrana

Hi Grace, I asked Dr Mauro this question last time. He said it is not approved yet. He also mentioned the ingredient is same as Pegasys but works longer with less side effects.

ggrana profile image
ggrana in reply toBeHealthy1986

I definitely want to try it I hope he agrees. I am pushing for it it sounds promising

Aneliv9 profile image
Aneliv9

Is there any country that Besremi is already approved???

in reply toAneliv9

Germany approved it and it has been in use since late 2019. I believe it has been approved by the EU as a whole and also some Asian countries

Aneliv9 profile image
Aneliv9 in reply to

So here in Greece ( Europe) do we have Besremi approved for PV?

in reply toAneliv9

Hi l think so as it was approved by the EU body for all 28 states plus Norway Iceland

aoporphan.com/po_en/our-com...

saturn0325 profile image
saturn0325 in reply toAneliv9

Taiwan has approved it.

MPNBlog profile image
MPNBlog

Many thanks for posting this link Manouche.

Maisie10 profile image
Maisie10

Thank you for sharing

Not what you're looking for?

You may also like...

ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results

https://www.vjhemonc.com/video/elvsbiyxlco-ropeg-in-polycythemia-vera-long-term-proud-pv-and-conti-p
Manouche profile image

BESREMI ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES

« No phlebotomies were required to maintain hematocrit <45% in the 6th year of treatment in 81.4%...
Manouche profile image

Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera

Summary of Results: Therapeutic phlebotomies were essentially eliminated and a target hematocrit...
Manouche profile image

Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach

 »In regard to PV, the decision to introduce cytoreduction may be more understandable than in ET....
Manouche profile image

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

«  Patients with PV often have high JAK2 V 617F VAF (>50%) because of the emergence of a dominant...
Manouche profile image